Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.61 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.61 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | GRM8 | O00222 | 1/20 | 0.52 |
| ▸ | GRM6 | O15303 | 1/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.52 |
| ▸ | GSR | P00390 | 1/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.52 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.52 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29531533 | 1.00 | DPP4 (0.61) | DPP4DPP8DPP9CYP1A2GRM8 | |
| SCHEMBL537129 | 1.00 | DPP4 (0.61) | DPP4DPP8DPP9CYP1A2GRM8 | |
| SCHEMBL29531781 | 0.97 | DPP4 (0.58) | DPP4DPP8DPP9CYP1A2GRM8 | |
| SCHEMBL29865375 | 0.94 | DPP4 (0.55) | DPP4DPP8DPP9CYP1A2GRM8 | |
| SCHEMBL30997439 | 0.92 | DPP4 (0.54) | DPP4DPP8DPP9CYP1A2GRM8 | |
| SCHEMBL6386178 | 0.92 | DPP4 (0.54) | DPP4DPP8DPP9CYP1A2GRM8 | |
| SCHEMBL18797432 | 0.92 | DPP4 (0.54) | DPP4DPP8DPP9CYP1A2GRM8 | |
| SCHEMBL31571451 | 0.91 | BACE1 (0.53) | DPP4DPP8DPP9CYP1A2GRM8 | |
| SCHEMBL31181278 | 0.91 | BACE1 (0.53) | DPP4DPP8DPP9BACE1CTSD | |
| SCHEMBL30483835 | 0.90 | BACE1 (0.54) | DPP4DPP8DPP9BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 328 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630456-A1 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND THERAPEUTIC USES THEREOF | Mythic Therapeutics, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| WO-2025103355-A1 | ANTI-EGFR AND -HER3 BISPECIFIC ANTIBODY-DRUG CONJUGATE AND USE THEREOF | 信达生物制药(苏州)有限公司 | 2025-05-22 | — | — | WO | claimed |
| US-20250115640-A1 | NEUROPROTECTIVE POLYPEPTIDE COMPOUND AND APPLICATION THEREOF | INNERSE (ZHUHAI) PHARMACEUTICAL CO., LTD. (CN) | 2025-04-10 | — | — | US | claimed |
| CN-118897023-B | Method for directly measuring alpha and gamma-glutamyl peptide in skeletal muscle by using LC-MS and isotope dilution assay | 中国农业科学院北京畜牧兽医研究所 | 2025-03-25 | — | — | CN | claimed |
| CN-118897023-A | Method for directly measuring alpha and gamma-glutamyl peptide in skeletal muscle by using LC-MS and isotope dilution assay | 中国农业科学院北京畜牧兽医研究所 | 2024-11-05 | — | — | CN | claimed |
| WO-2024193692-A1 | LINKER AND USE THEREOF IN LIGAND DRUG CONJUGATE | 映恩生物制药（苏州）有限公司 | 2024-09-26 | — | — | WO | claimed |
| US-20240197906-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND THERAPEUTIC USES THEREOF | MYTHIC THERAPEUTICS, INC. | 2024-06-20 | — | — | US | claimed |
| WO-2024129585-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND THERAPEUTIC USES THEREOF | MYTHIC THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| EP-4378949-A1 | NEUROPROTECTIVE POLYPEPTIDE COMPOUND AND APPLICATION THEREOF | Innerse (Zhuhai) Pharmaceutical Co., Ltd. (CN) | 2024-06-05 | — | — | EP | claimed |
| EP-4364754-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2024-05-08 | — | — | EP | claimed |
| US-20150065460-A1 | Biomarkers Related to Insulin Resistance and Methods Using the Same | METABOLON, INC. | 2015-03-05 | — | — | US | claimed |
| EP-2546649-B1 | Biomarkers for fatty liver disease and methods using the same | METABOLON INC (US) | 2015-02-25 | — | — | EP | claimed |
| EP-2756095-A1 | BIOMARKERS RELATED TO INSULIN RESISTANCE AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2014-07-23 | — | — | EP | claimed |
| WO-2013039898-A1 | BIOMARKERS RELATED TO INSULIN RESISTANCE AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-03-21 | — | — | WO | claimed |
| EP-2546649-A2 | Biomarkers for fatty liver disease and methods using the same | Metabolon Inc. (US) | 2013-01-16 | — | — | EP | claimed |
| EP-2227689-B1 | BIOMARKERS FOR FATTY LIVER DISEASE AND METHODS USING THE SAME | METABOLON INC (US) | 2012-12-26 | — | — | EP | claimed |
| US-20120122981-A1 | Biomarkers Related to Insulin Resistance and Methods using the Same | METABOLON, INC. | 2012-05-17 | — | — | US | claimed |
| EP-2414535-A1 | BIOMARKERS RELATED TO INSULIN RESISTANCE AND METHODS USING THE SAME | Metabolon Inc. (US) | 2012-02-08 | — | — | EP | claimed |
| US-20100279956-A1 | Biomarkers For Fatty Liver Disease And Methods Using The Same | METABOLON, INC. | 2010-11-04 | — | — | US | claimed |
| WO-2010114897-A1 | BIOMARKERS RELATED TO INSULIN RESISTANCE AND METHODS USING THE SAME | METABOLON, INC. (US) | 2010-10-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197906-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND THERAPEUTIC USES THEREOF | MET, EGFR, SLC5A7 | DPP4 1918/4885DPP8 1863/4885DPP9 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.